NTLA
Intellia Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +12.5% ·
share flow +0.9% ·
net new positions +5.6%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | +1 | 344.29K | $4.16M | +1 | −1 |
| Q2 2026 | 107 | +3 | 103.07M | $1.74B | +8 | −6 |
| Q1 2026 | 108 | +4 | 82.71M | $1.06B | +13 | −9 |
| Q4 2025 | 104 | -1 | 82.78M | $744.21M | +1 | −2 |
| Q3 2025 | 18 | +2 | 59.30M | $1.02B | +2 | −1 |
| Q2 2025 | 14 | +2 | 47.63M | $446.74M | +2 | n/a |
| Q1 2025 | 9 | -4 | 25.51M | $181.35M | n/a | −4 |
| Q4 2024 | 13 | +3 | 26.17M | $305.16M | +3 | n/a |
| Q3 2024 | 9 | 0 | 18.08M | $371.64M | +1 | −1 |
| Q2 2024 | 9 | n/a | 17.86M | $399.79M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | ARK Investment Management ✦ | 11.92M | -8.4% | $205.84M | 1.2% | ▼ Trim | 6 | SEC ↗ |
| 2 | The Vanguard Group ✦ (passive) | 11.04M | +1.8% | $190.74M | 0.0% | ▲ Add | 2 | SEC ↗ ×6 |
| 3 | BlackRock ✦ (passive) | 9.28M | -7.5% | $160.19M | 0.0% | ▼ Trim | 2 | SEC ↗ ×15 |
| 4 | Morgan Stanley ✦ | 6.02M | n/a | $104.01M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 5 | State Street Global Advisors ✦ (passive) | 4.97M | +23.1% | $85.85M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Goldman Sachs Group ✦ | 4.28M | n/a | $73.89M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 7 | Geode Capital Management ✦ (passive) | 2.59M | -0.7% | $44.71M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 8 | Two Sigma Investments ✦ | 2.45M | +7.6% | $42.30M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 9 | D. E. Shaw & Co. ✦ | 2.23M | +170.2% | $38.48M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 10 | Fidelity (FMR) ✦ | 1.85M | +21.8% | $31.99M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 11 | JPMorgan Chase ✦ | 881.14K | n/a | $15.22M | 0.0% | n/c | 1 | SEC ↗ ×14 |
| 12 | Renaissance Technologies ✦ | 651.00K | -3.8% | $11.24M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 13 | Millennium Management ✦ | 607.56K | -26.9% | $10.49M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 210.41K | +54.1% | $3.63M | 0.0% | ▲ Add | 4 | SEC ↗ ×4 |
| 15 | Point72 Asset Management ✦ | 174.26K | New | $3.01M | 0.0% | New | 1 | SEC ↗ |
| 16 | T. Rowe Price ✦ | 92.51K | +80.9% | $1.60M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 17 | Wellington Management ✦ | 44.53K | New | $769,016 | 0.0% | New | 1 | SEC ↗ ×4 |
| 18 | Citadel Advisors ✦ | 10.36K | -98.5% | $178,831 | 0.0% | ▼ Trim | 6 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $3.01M | 0.0% |
| Wellington Management | $769,016 | 0.0% |
Exited
| Norges Bank | $534,088 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 22.80K shares, $292 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 1.86K sh · $23,170
Officer, Director · 2.79K sh · $36,205
Officer, Director · 19.89K sh · $250,614
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology